Are SGLT2 inhibitors joining the mainstream therapy for diabetes type 2?
MF Hassanabad, ZFH Abad - … & metabolic syndrome: clinical research & …, 2019 - Elsevier
Background Conventional therapies to prevent type 2 diabetes mellitus (T2DM)
complications are only partially effective. Therefore, new therapeutic approaches leading to
additional risk reduction are required. While many anti-diabetic medications have been
prescribed world-wide for controlling T2DM over the past half-century, sodium-glucose co-
transporter-2 (SGLT2) inhibitors are relatively new. In addition to their plasma glucose
lowering effect, SGLT2 inhibitors have been shown to reduce considerably cardiovascular …
complications are only partially effective. Therefore, new therapeutic approaches leading to
additional risk reduction are required. While many anti-diabetic medications have been
prescribed world-wide for controlling T2DM over the past half-century, sodium-glucose co-
transporter-2 (SGLT2) inhibitors are relatively new. In addition to their plasma glucose
lowering effect, SGLT2 inhibitors have been shown to reduce considerably cardiovascular …